Therapeutic Asset Ratings
159 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Cediranib
Adenocarcinoma of the Pancreas
University Health Network, Toronto
P3
BB
(70)
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Headache
University Health Network, Toronto
P4
BB
(69)
CIS-DIAMMINEDICHLOROPLATINUM II
BRCA1 Mutation Carrier
University Health Network, Toronto
P2/3
BB
(68)
Capecitabine
Stage IV Breast Cancer
University Health Network, Toronto
P3
BB
(66)
Eloxatin
Stage IV Breast Cancer
University Health Network, Toronto
P3
BB
(66)
Relatlimab
Cutaneous Melanoma
University Health Network, Toronto
P3
BB
(66)
Inno-206
Duct Cell Adenocarcinoma of the Pancreas
University Health Network, Toronto
P2
BB
(66)
Indocyanine Green
Ulcer, Gastric
University Health Network, Toronto
P4
BB
(65)
Semaglutide
Liver Transplant; Complications
University Health Network, Toronto
P4
BB
(65)
Sitagliptin
Liver Transplant; Complications
University Health Network, Toronto
P4
BB
(65)
Sitagliptin
Non-alcoholic Fatty Liver Disease
University Health Network, Toronto
P4
BB
(64)
LIDOCAINE
Post-mastectomy Pain Syndrome
University Health Network, Toronto
P3
BB
(64)
Rivaroxaban
Sickle Cell Anemia
University Health Network, Toronto
P3
BB
(64)
Enasidenib
IDH2 Gene Mutation
University Health Network, Toronto
P2
BB
(64)
CIS-DIAMMINEDICHLOROPLATINUM II
BRCA1/2 Mutation
University Health Network, Toronto
P2/3
BB
(64)
Brigatinib
Advanced Malignancies
University Health Network, Toronto
P3
B
(63)
TAMOXIFEN
Prostate Cancer
University Health Network, Toronto
P3
B
(63)
Selinexor
Duct Cell Adenocarcinoma of the Pancreas
University Health Network, Toronto
P2
B
(63)
Cediranib
Colorectal Cancer
University Health Network, Toronto
P4
B
(62)
Indocyanine Green
Obesity, Morbid
University Health Network, Toronto
P4
B
(62)
Vinorelbine
Cancer
University Health Network, Toronto
P3
B
(62)
TAMOXIFEN
Hypogonadism
University Health Network, Toronto
P2
B
(62)
Atezolizumab
Ovarian Endometrioid Tumor
University Health Network, Toronto
P2/3
B
(62)
Tocilizumab
Refractory Cancer
University Health Network, Toronto
P4
B
(61)
Cediranib
Adult Leiomyosarcoma
University Health Network, Toronto
P2
B
(61)
Showing 1 to 25 of 159 assets
Previous
Page 1 of 7
Next